Adenoviral vectors: Systemic delivery and tumor targeting
- 22 November 2002
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (12) , 1036-1042
- https://doi.org/10.1038/sj.cgt.7700541
Abstract
The development of a targeted adenoviral vector, which can be delivered systemically, is one of the major challenges facing cancer gene therapy. The virus is readily cleared from the bloodstream, can be neutralised by pre-existing antibodies, and has a permissive cellular tropism. Clinical studies using the ONYX virus have shown limited efficacy, but there are several hurdles to overcome to achieve an effective tumor-specific systemic therapy. In this review, we have summarized the various strategies used to overcome the limitations of adenoviral-mediated gene delivery.Keywords
This publication has 58 references indexed in Scilit:
- Impact of Preimmunization on Adenoviral Vector Expression and Toxicity in a Subcutaneous Mouse Cancer ModelMolecular Therapy, 2002
- Complement activation by recombinant adenovirusesGene Therapy, 2001
- Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigenJournal of Clinical Investigation, 2000
- Special Clinical SessionMolecular Therapy, 2000
- NAS Report Under ScrutinyScience, 2000
- Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epitheliaJournal of Clinical Investigation, 2000
- Brief Report: Liver Bypass Significantly Increases the Transduction Efficiency of Recombinant Adenoviral Vectors in the Lung, Intestine, and KidneyHuman Gene Therapy, 2000
- Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vectorThe Journal of Gene Medicine, 1999
- Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancerGene Therapy, 1999
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993